Menu
Recruiting NCT06169241

Effect of Nitrate Supplementation on Blood Pressure and Microvascular Function of Resistant Hypertensive Patients

Early Phase I Interventional Arterial Hypertension Resistant Hypertension Microvascular Function Nitrate Supplementation

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Beetroot extract, Placebo.
Who it may be relevant to
Registry conditions: Arterial Hypertension, Resistant Hypertension, Microvascular Function, Nitrate Supplementation. Basic parameters: 18 years — 75 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Brazil
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Effect of Nitrate Supplementation on Blood Pressure and Systemic Microvascular Function of Resistant Hypertensive Patients

Overview

Arterial hypertension (AH) has been identified as an important public health problem and considered a new epidemic with high mortality and morbidity. High blood pressure (BP) levels increase the chances of coronary artery disease (CAD), heart failure (HF), stroke, chronic renal failure (CRF) and death. Beetroot powder may be an easier way to increase the availability of nitric oxide and consequently vasodilation in these patients. However, studies are needed to evaluate its benefits in patients with AH.

Interventions

  • Dietary supplement Beetroot extract
    Beetroot extract powder supplementation with 400mg of nitrate per dose in the amount of 10g per day orally will be used in the group.
  • Dietary supplement Placebo
    The placebo will be administered as a colored and flavored isocaloric supplement composed of maltodextrin.

Primary outcome measures

  • Assessment of blood pressure evolution [Time frame: 60 days]

Eligibility criteria

Inclusion criteria

  • Resistant hypertension, with a diagnosis described in the medical record, without changing medications or increasing doses in the last 30 days.

Exclusion criteria

  • neoplasms
  • heart failure
  • use of medications with nitrate in their formula
  • patients undergoing renal denervation

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Crossover
Masking
Quadruple blind
Primary purpose
Treatment

Study locations

Brazil · 1 center
  • National Institute of Cardiology — Rio de Janeiro

Identifiers

NCT: NCT06169241 · 70847523.9.0000.5272

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗